文章：

胰腺导管腺癌患者治疗模式的转变与生存率的提升

Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma

原文发布日期：7 September 2023

DOI: 10.3390/cancers15184464

类型: Article

开放获取: 是

英文摘要：

Over the last two decades, there have been many reported advances in the clinical management of pancreatic ductal adenocarcinoma (PDAC). We sought to evaluate changes in survival for patients diagnosed with PDAC between 2004 and 2017. The National Cancer Database was queried for patients diagnosed with PDAC between 2004 and 2017. There were 55,401 patients who underwent surgery and 109,477 patients who underwent non-surgical treatment for PDAC between 2004 and 2017. Patients were categorized into four groups by year of diagnosis. Median survival improved from 15.5 months to 25.3 months for patients treated with surgery between the years 2016 and 2017 compared with between 2004 and 2007 (p< 0.001). Median survival improved from 7.2 months to 10.1 months for patients treated without surgery during the same years (p< 0.001). On multivariable analysis, the hazard ratio for death was estimated to multiply by 0.975 per year for patients treated with surgery and 0.959 per year for patients treated without surgery (p< 0.001). This increase in survival in the setting of evolving care validates continued efforts aimed at improving survival for patients with this devastating disease.

摘要翻译： 

过去二十年间，胰腺导管腺癌（PDAC）的临床管理领域已取得诸多进展。本研究旨在评估2004年至2017年间确诊PDAC患者生存率的变化趋势。通过检索美国国家癌症数据库，共纳入2004-2017年间接受手术治疗的55,401例患者及接受非手术治疗的109,477例PDAC患者。按确诊年份将患者分为四组进行分析。结果显示：与2004-2007年相比，2016-2017年间接受手术治疗的患者中位生存期从15.5个月提升至25.3个月（p<0.001）；同期接受非手术治疗的患者中位生存期从7.2个月提升至10.1个月（p<0.001）。多变量分析表明，手术治疗患者的死亡风险比每年降低2.5%（HR=0.975/年），非手术治疗患者每年降低4.1%（HR=0.959/年）（p<0.001）。在医疗模式持续演进的背景下，患者生存期的显著延长验证了当前为改善这一危重疾病患者预后所付出努力的有效性。

原文链接：

Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma